Drug Type Biosimilar, Colony-stimulating factors |
Synonyms Filgrastim Biosimilar (Tanvex BioPharma, Inc.), 非格司亭 生物类似药(Tanvex BioPharma, Inc.) + [1] |
Target |
Action agonists |
Mechanism CSF-3R agonists(Colony stimulating factor 3 receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date Canada (01 Oct 2021), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Filgrastim-txid |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Myeloid Leukemia | United States | 28 Jun 2024 | |
Bone marrow depression | United States | 28 Jun 2024 | |
Neutropenia | Canada | 01 Oct 2021 |